RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome
Research output: Contribution to journal › Journal article › Research › peer-review
To establish the safety, tolerability and most promising regimen of darexaban (YM150), a novel, oral, direct factor Xa inhibitor, for prevention of ischaemic events in acute coronary syndrome (ACS).
Original language | English |
---|---|
Journal | European Heart Journal (Online) |
Volume | 32 |
Issue number | 20 |
Pages (from-to) | 2541-54 |
Number of pages | 14 |
ISSN | 1522-9645 |
DOIs | |
Publication status | Published - Oct 2011 |
ID: 48592247